Yang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yang Yang has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Jing Su
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China
14 shared publications- Fang Lu
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
13 shared publications Xiu Jin
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China
13 shared publicationsLi Song
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China
10 shared publicationsRuiting Li
State Key Laboratory of Biotherapy West China Hospital Chengdu Sichuan China
9 shared publicationsFanfei Liu
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
8 shared publications
Latest Publications
- 23 October 2026
- Published by Elsevier in Trends in Molecular Medicine
Rethinking nonsense suppression therapies in inherited retinal diseases
- 23 October 2026
- Published by Elsevier in Trends in Molecular Medicine
Rethinking nonsense suppression therapies in inherited retinal diseases
- 16 October 2026
- Published by SAGE Publications in Human Gene Therapy
Ocular Gene Therapy in China: Technological Framework, Clinical Translation, and Future Perspectives
The eye is well suited to gene therapy because of its compartmentalized anatomy, accessibility for local delivery, and capacity for longitudinal assessment. In China, ocular gene therapy is undergoing rapid clinical translation, with expanding innovation in vector engineering, delivery technologies, genome editing, and therapeutic modalities. Clinical development has progressed from inherited optic neuropathies and retinal diseases to complex acquired ocular disorders, anterior-segment genome editing, and optogenetic vision restoration. This review summarizes the technological landscape and representative clinical advances of ocular gene therapy in China, highlighting the evolution from established gene-replacement approaches toward increasingly differentiated therapeutic strategies. We further discuss key challenges in interpreting clinical benefit and translating early clinical signals into durable, reproducible outcomes. Future progress will depend on clinically driven innovation, rigorous evidence of meaningful patient benefit, and standardized pathways for sustainable clinical translation.
- 16 October 2026
- Published by SAGE Publications in Human Gene Therapy
Ocular Gene Therapy in China: Technological Framework, Clinical Translation, and Future Perspectives
The eye is well suited to gene therapy because of its compartmentalized anatomy, accessibility for local delivery, and capacity for longitudinal assessment. In China, ocular gene therapy is undergoing rapid clinical translation, with expanding innovation in vector engineering, delivery technologies, genome editing, and therapeutic modalities. Clinical development has progressed from inherited optic neuropathies and retinal diseases to complex acquired ocular disorders, anterior-segment genome editing, and optogenetic vision restoration. This review summarizes the technological landscape and representative clinical advances of ocular gene therapy in China, highlighting the evolution from established gene-replacement approaches toward increasingly differentiated therapeutic strategies. We further discuss key challenges in interpreting clinical benefit and translating early clinical signals into durable, reproducible outcomes. Future progress will depend on clinically driven innovation, rigorous evidence of meaningful patient benefit, and standardized pathways for sustainable clinical translation.
- Open Access
- 17 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11185
AAV-delivered engineered suppressor tRNA rescues visual function in mice with an inherited retinal disease
Nonsense mutations change a sense codon into a premature termination codon (PTC) in mRNA and account for approximately 18.5% of human inherited retinal diseases (IRDs)-related mutation. Nonsense suppression therapies by small molecular drugs or suppressor tRNAs (sup-tRNAs) can introduce an amino acid at PTC, thereby promoting the production of full-length proteins. While sup-tRNA-based therapies have shown promising results in cell culture models, challenges remain for in vivo delivery, particularly regarding efficacy, stability, and safety. In this study, we engineer the body sequence of sup-tRNAArg to enhance readthrough efficiency at clinically relevant PTCs in the RPE65 and ABCA4 genes. By using the self-complementary adeno-associated virus (scAAV), we achieve restoration of RPE65 protein expression in up to 50.2% retinal pigment epithelium (RPE) cells in a mouse model carrying the RPE65-R44X nonsense mutation. Notably, the engineered sup-tRNAArg significantly restores retinal function in mice, with effects lasting for at least 36 weeks. Furthermore, scAAV8.sup-tRNAArg exhibits minimal retinal toxicity and had negligible effects on global readthrough at native termination codons as revealed by ribosome profiling. Our findings demonstrate scAAV-delivered sup-tRNAArg is a potential therapeutic intervention for IRDs caused by nonsense mutations in RPE65 gene.
- 17 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11185
Open AccessAAV-delivered engineered suppressor tRNA rescues visual function in mice with an inherited retinal disease
Nonsense mutations change a sense codon into a premature termination codon (PTC) in mRNA and account for approximately 18.5% of human inherited retinal diseases (IRDs)-related mutation. Nonsense suppression therapies by small molecular drugs or suppressor tRNAs (sup-tRNAs) can introduce an amino acid at PTC, thereby promoting the production of full-length proteins. While sup-tRNA-based therapies have shown promising results in cell culture models, challenges remain for in vivo delivery, particularly regarding efficacy, stability, and safety. In this study, we engineer the body sequence of sup-tRNAArg to enhance readthrough efficiency at clinically relevant PTCs in the RPE65 and ABCA4 genes. By using the self-complementary adeno-associated virus (scAAV), we achieve restoration of RPE65 protein expression in up to 50.2% retinal pigment epithelium (RPE) cells in a mouse model carrying the RPE65-R44X nonsense mutation. Notably, the engineered sup-tRNAArg significantly restores retinal function in mice, with effects lasting for at least 36 weeks. Furthermore, scAAV8.sup-tRNAArg exhibits minimal retinal toxicity and had negligible effects on global readthrough at native termination codons as revealed by ribosome profiling. Our findings demonstrate scAAV-delivered sup-tRNAArg is a potential therapeutic intervention for IRDs caused by nonsense mutations in RPE65 gene.
- Open Access
- 10 December 2025
- Published by Elsevier in Molecular Therapy
- Vol. 34 (3) , 1775-1793
Comparative evaluation of liver-directed knockin strategies with viral and nonviral vectors in mouse inherited disease models
- 10 December 2025
- Published by Elsevier in Molecular Therapy
- Vol. 34 (3) , 1775-1793
Open AccessComparative evaluation of liver-directed knockin strategies with viral and nonviral vectors in mouse inherited disease models
- Open Access
Retinal Pigment Epithelium‐Targeting Gene Therapy Corrects Ocular Symptoms in Mouse and Rat Models of Oculocutaneous Albinism Type I
Oculocutaneous albinism (OCA) represents a genetically heterogeneous autosomal recessive condition marked by reduced melanin production in cutaneous and ocular tissues. This disorder primarily arises from mutations in the TYR gene, which encodes tyrosinase—the rate‐limiting enzyme in melanogenesis. Such genetic defects lead to impaired or absent tyrosinase activity, consequently causing melanin deficiency. Currently, no curative treatment exists for OCA1. In this study, we investigated the efficacy of AAV vector‐based gene therapy in two murine models of OCA1, evaluating its potential as a therapeutic intervention. B6 albino mice were injected with three AAV8 vectors containing distinct promoters at different dosages, among which AAV8.hRPE65p.hTYRco showed the best therapeutic effect at a dose of 1 × 10 9 GC/eye. This RPE‐targeted strategy restored the expression of functional tyrosinase and melanin deposition in the RPE layer. More importantly, the retinal structure and visual function were maintained at nearly normal levels for up to 12 months, with no obvious toxicity. In addition, we demonstrated that the suprachoroidal cavity delivery of AAV8.hRPE65p.hTYRco restored the expression of tyrosinase and relieved ocular dysfunction in Wistar rats for at least 12 months. The results revealed a long‐term, effective, safe strategy for treating OCA1.
Open AccessRetinal Pigment Epithelium‐Targeting Gene Therapy Corrects Ocular Symptoms in Mouse and Rat Models of Oculocutaneous Albinism Type I
Oculocutaneous albinism (OCA) represents a genetically heterogeneous autosomal recessive condition marked by reduced melanin production in cutaneous and ocular tissues. This disorder primarily arises from mutations in the TYR gene, which encodes tyrosinase—the rate‐limiting enzyme in melanogenesis. Such genetic defects lead to impaired or absent tyrosinase activity, consequently causing melanin deficiency. Currently, no curative treatment exists for OCA1. In this study, we investigated the efficacy of AAV vector‐based gene therapy in two murine models of OCA1, evaluating its potential as a therapeutic intervention. B6 albino mice were injected with three AAV8 vectors containing distinct promoters at different dosages, among which AAV8.hRPE65p.hTYRco showed the best therapeutic effect at a dose of 1 × 10 9 GC/eye. This RPE‐targeted strategy restored the expression of functional tyrosinase and melanin deposition in the RPE layer. More importantly, the retinal structure and visual function were maintained at nearly normal levels for up to 12 months, with no obvious toxicity. In addition, we demonstrated that the suprachoroidal cavity delivery of AAV8.hRPE65p.hTYRco restored the expression of tyrosinase and relieved ocular dysfunction in Wistar rats for at least 12 months. The results revealed a long‐term, effective, safe strategy for treating OCA1.
- Open Access
- 23 September 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (6) , e00741
Rescue of neurologic disease in mucopolysaccharidosis type II mice via AAV-mediated liver delivery of brain-penetrating iduronate-2-sulfatase
- 23 September 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (6) , e00741
Open AccessRescue of neurologic disease in mucopolysaccharidosis type II mice via AAV-mediated liver delivery of brain-penetrating iduronate-2-sulfatase
- Open Access
- 2 September 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (12) , 29
RP1 Dual-AAV Gene Therapy Preserves Retinal Structure and Ameliorates Photoreceptor Degeneration in a Murine Model of Retinitis Pigmentosa
This study aimed to develop and compare dual-adeno-associated virus (AAV) gene therapy utilizing protein trans-splicing versus mRNA trans-splicing to restore RP1 expression, and to evaluate their safety and efficacy in rescuing photoreceptor degeneration in a mouse model of RP1-associated retinitis pigmentosa (RP). By screening various split sites within the RP1 sequence in combination with different inteins or adopting mRNA trans-splicing binding sequences, we generated several plasmid pairs capable of reconstituting RP1 in vitro. Next, we conducted dual-AAV gene therapy via subretinal injection in RP1-/- mice. We validated the RP1 protein reconstitution in vivo by Western blotting. To assess the safety and efficacy of dual-AAV systems in RP1-/- mice, retinal structure was evaluated by histological analysis and transmission electron microscopy (TEM), and visual function was assessed by electroretinography (ERG) and visually guided behavioral tests at 1 and 6 months post-treatment. The protein trans-splicing dual-AAV system achieved 72.35% of wild-type RP1 expression levels, significantly outperforming the mRNA trans-splicing approach (37.84%) at 1 month post-treatment. Both dual-AAV gene therapies preserved photoreceptor morphology and restored retinal function. The protein trans-splicing dual-AAV system exhibited higher ERG amplitudes and better performance in the water maze than the mRNA trans-splicing system. Our study demonstrates protein trans-splicing mediated dual-AAV gene therapy as a promising strategy for RP1-associated RP, offering potential therapeutic avenue for patients with RP.
- 2 September 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (12) , 29
Open AccessRP1 Dual-AAV Gene Therapy Preserves Retinal Structure and Ameliorates Photoreceptor Degeneration in a Murine Model of Retinitis Pigmentosa
This study aimed to develop and compare dual-adeno-associated virus (AAV) gene therapy utilizing protein trans-splicing versus mRNA trans-splicing to restore RP1 expression, and to evaluate their safety and efficacy in rescuing photoreceptor degeneration in a mouse model of RP1-associated retinitis pigmentosa (RP). By screening various split sites within the RP1 sequence in combination with different inteins or adopting mRNA trans-splicing binding sequences, we generated several plasmid pairs capable of reconstituting RP1 in vitro. Next, we conducted dual-AAV gene therapy via subretinal injection in RP1-/- mice. We validated the RP1 protein reconstitution in vivo by Western blotting. To assess the safety and efficacy of dual-AAV systems in RP1-/- mice, retinal structure was evaluated by histological analysis and transmission electron microscopy (TEM), and visual function was assessed by electroretinography (ERG) and visually guided behavioral tests at 1 and 6 months post-treatment. The protein trans-splicing dual-AAV system achieved 72.35% of wild-type RP1 expression levels, significantly outperforming the mRNA trans-splicing approach (37.84%) at 1 month post-treatment. Both dual-AAV gene therapies preserved photoreceptor morphology and restored retinal function. The protein trans-splicing dual-AAV system exhibited higher ERG amplitudes and better performance in the water maze than the mRNA trans-splicing system. Our study demonstrates protein trans-splicing mediated dual-AAV gene therapy as a promising strategy for RP1-associated RP, offering potential therapeutic avenue for patients with RP.
- 20 August 2025
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 21 (8) , 2386-2406
Advances in Stem Cell Therapies for Ocular Diseases: Progress in Clinical Trials and Future Perspectives
Stem cell-based therapies hold promise for vision-threatening ocular diseases by promoting tissue repair and restoring visual function. Stem cells are classified by differentiation potential into two main types. Pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), possess the capacity to differentiate into somatic cells. Multipotent adult stem cells, such as mesenchymal stem cells (MSCs), are restricted to differentiating into cell types within specific lineages. The therapeutic potential of stem cells is discussed in the context of treating corneal diseases, glaucoma, and retinal disorders such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). This review focuses on the clinical trials of stem cell therapies for ocular diseases and discusses prospects in the field. Despite the considerable promise of these preclinical results in restoring visual function, significant challenges in clinical application remain, such as insufficient long-term cell survival, incomplete functional integration into host tissues, and the potential risk of oncogenic transformation. Future progress will depend on the development of standardized protocols, efficient delivery methods, and interdisciplinary collaboration to effectively translate preclinical advances into clinical applications. Graphical Abstract
- 20 August 2025
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 21 (8) , 2386-2406
Advances in Stem Cell Therapies for Ocular Diseases: Progress in Clinical Trials and Future Perspectives
Stem cell-based therapies hold promise for vision-threatening ocular diseases by promoting tissue repair and restoring visual function. Stem cells are classified by differentiation potential into two main types. Pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), possess the capacity to differentiate into somatic cells. Multipotent adult stem cells, such as mesenchymal stem cells (MSCs), are restricted to differentiating into cell types within specific lineages. The therapeutic potential of stem cells is discussed in the context of treating corneal diseases, glaucoma, and retinal disorders such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). This review focuses on the clinical trials of stem cell therapies for ocular diseases and discusses prospects in the field. Despite the considerable promise of these preclinical results in restoring visual function, significant challenges in clinical application remain, such as insufficient long-term cell survival, incomplete functional integration into host tissues, and the potential risk of oncogenic transformation. Future progress will depend on the development of standardized protocols, efficient delivery methods, and interdisciplinary collaboration to effectively translate preclinical advances into clinical applications. Graphical Abstract
- Open Access
- 8 August 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 190, 118423
Visual cycle and LC3-associated phagocytosis in retina: regulatory mechanisms and therapeutic potential
- 8 August 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 190, 118423
Open AccessVisual cycle and LC3-associated phagocytosis in retina: regulatory mechanisms and therapeutic potential
- Open Access
- 25 April 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-16
A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury
The ubiquitin-editing enzyme A20 is known to regulate inflammation and maintain homeostasis, but its role in self-DNA-mediated inflammation in acute kidney injury (AKI) is not well understood. Here, our study demonstrated that oxidized self-DNA accumulates in the serum of AKI mice and patients. This oxidized self-DNA exacerbates the progression of AKI by activating the cGAS-STING pathway and NLRP3 inflammasome. While inhibition of the STING pathway only slightly attenuates AKI progression, suppression of NLRP3 inflammasome-mediated pyroptosis significantly alleviates AKI progression and improves the survival of AKI mice. Subsequently, we found that Tnfaip3 (encoding A20) is significantly upregulated following oxidized self-DNA treatment. A20 significantly alleviates AKI development by dampening STING signaling pathway and NLRP3-mediated pyroptosis. Moreover, A20-derived peptide (P-II) also significantly alleviates ox-dsDNA-induced pyroptosis and improves the survival and renal injury of AKI mice. Mechanistically, A20 competitively binds with NEK7 and thus inhibiting NLRP3 inflammasome. A20 and P-II interfere with the interaction between NEK7 and NLRP3 through Lys140 of NEK7. Mutation of Lys140 effects on the interaction of NEK7 with A20 and/or NLRP3 complex. Conditional knockout of NEK7 in macrophages or pharmacological inhibition of NEK7 both significantly rescue AKI mouse models. This study reveals a new mechanism by which A20 attenuates oxidized self-DNA-mediated inflammation and provides a new therapeutic strategy for AKI.
- 25 April 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-16
Open AccessA20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury
The ubiquitin-editing enzyme A20 is known to regulate inflammation and maintain homeostasis, but its role in self-DNA-mediated inflammation in acute kidney injury (AKI) is not well understood. Here, our study demonstrated that oxidized self-DNA accumulates in the serum of AKI mice and patients. This oxidized self-DNA exacerbates the progression of AKI by activating the cGAS-STING pathway and NLRP3 inflammasome. While inhibition of the STING pathway only slightly attenuates AKI progression, suppression of NLRP3 inflammasome-mediated pyroptosis significantly alleviates AKI progression and improves the survival of AKI mice. Subsequently, we found that Tnfaip3 (encoding A20) is significantly upregulated following oxidized self-DNA treatment. A20 significantly alleviates AKI development by dampening STING signaling pathway and NLRP3-mediated pyroptosis. Moreover, A20-derived peptide (P-II) also significantly alleviates ox-dsDNA-induced pyroptosis and improves the survival and renal injury of AKI mice. Mechanistically, A20 competitively binds with NEK7 and thus inhibiting NLRP3 inflammasome. A20 and P-II interfere with the interaction between NEK7 and NLRP3 through Lys140 of NEK7. Mutation of Lys140 effects on the interaction of NEK7 with A20 and/or NLRP3 complex. Conditional knockout of NEK7 in macrophages or pharmacological inhibition of NEK7 both significantly rescue AKI mouse models. This study reveals a new mechanism by which A20 attenuates oxidized self-DNA-mediated inflammation and provides a new therapeutic strategy for AKI.